Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α

5-year outcome

Francesca Palandri, Ilaria Iacobucci, Fausto Castagnetti, Nicoletta Testoni, Angela Poerio, Marilina Amabile, Massimo Breccia, Tamara Intermesoli, Francesco Iuliano, Giovanna Rege-Cambrin, Mario Tiribelli, Maurizio Miglino, Fabrizio Pane, Giuseppe Saglio, Giovanni Martinelli, Gianantonio Rosti, Michele Baccarani

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg daily and pegylated interferon-α in the treatment of 76 early chronic phase Philadelphia-positive chronic myeloid leukemia patients. In this report, we update the results with an observation time of five years. After two years of treatment, all but 10 patients (13%) had discontinued pegylated interferon-α. The complete cytogenetic response rate at five years was 87%, and 94% of complete cytogenetic responders maintained the complete cytogenetic response after five years. All but one complete cytogenetic response also achieved a major molecular response. These data confirm the excellent response to imatinib front-line and the stability of the complete cytogenetic response. Any possible additional benefit of the combination with interferon-a remains uncertain, due to low patient compliance.

Original languageEnglish
Pages (from-to)770-774
Number of pages5
JournalHaematologica
Volume93
Issue number5
DOIs
Publication statusPublished - May 2008

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Interferons
Therapeutics
Patient Compliance
Observation
Imatinib Mesylate

Keywords

  • Chronic myeloid leukemia
  • Imatinib
  • Interferon-alpha
  • Long-term results

ASJC Scopus subject areas

  • Hematology

Cite this

Palandri, F., Iacobucci, I., Castagnetti, F., Testoni, N., Poerio, A., Amabile, M., ... Baccarani, M. (2008). Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α: 5-year outcome. Haematologica, 93(5), 770-774. https://doi.org/10.3324/haematol.12265

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α : 5-year outcome. / Palandri, Francesca; Iacobucci, Ilaria; Castagnetti, Fausto; Testoni, Nicoletta; Poerio, Angela; Amabile, Marilina; Breccia, Massimo; Intermesoli, Tamara; Iuliano, Francesco; Rege-Cambrin, Giovanna; Tiribelli, Mario; Miglino, Maurizio; Pane, Fabrizio; Saglio, Giuseppe; Martinelli, Giovanni; Rosti, Gianantonio; Baccarani, Michele.

In: Haematologica, Vol. 93, No. 5, 05.2008, p. 770-774.

Research output: Contribution to journalArticle

Palandri, F, Iacobucci, I, Castagnetti, F, Testoni, N, Poerio, A, Amabile, M, Breccia, M, Intermesoli, T, Iuliano, F, Rege-Cambrin, G, Tiribelli, M, Miglino, M, Pane, F, Saglio, G, Martinelli, G, Rosti, G & Baccarani, M 2008, 'Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α: 5-year outcome', Haematologica, vol. 93, no. 5, pp. 770-774. https://doi.org/10.3324/haematol.12265
Palandri, Francesca ; Iacobucci, Ilaria ; Castagnetti, Fausto ; Testoni, Nicoletta ; Poerio, Angela ; Amabile, Marilina ; Breccia, Massimo ; Intermesoli, Tamara ; Iuliano, Francesco ; Rege-Cambrin, Giovanna ; Tiribelli, Mario ; Miglino, Maurizio ; Pane, Fabrizio ; Saglio, Giuseppe ; Martinelli, Giovanni ; Rosti, Gianantonio ; Baccarani, Michele. / Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α : 5-year outcome. In: Haematologica. 2008 ; Vol. 93, No. 5. pp. 770-774.
@article{733cce2f089d44f98478694cdbe378a9,
title = "Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α: 5-year outcome",
abstract = "In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg daily and pegylated interferon-α in the treatment of 76 early chronic phase Philadelphia-positive chronic myeloid leukemia patients. In this report, we update the results with an observation time of five years. After two years of treatment, all but 10 patients (13{\%}) had discontinued pegylated interferon-α. The complete cytogenetic response rate at five years was 87{\%}, and 94{\%} of complete cytogenetic responders maintained the complete cytogenetic response after five years. All but one complete cytogenetic response also achieved a major molecular response. These data confirm the excellent response to imatinib front-line and the stability of the complete cytogenetic response. Any possible additional benefit of the combination with interferon-a remains uncertain, due to low patient compliance.",
keywords = "Chronic myeloid leukemia, Imatinib, Interferon-alpha, Long-term results",
author = "Francesca Palandri and Ilaria Iacobucci and Fausto Castagnetti and Nicoletta Testoni and Angela Poerio and Marilina Amabile and Massimo Breccia and Tamara Intermesoli and Francesco Iuliano and Giovanna Rege-Cambrin and Mario Tiribelli and Maurizio Miglino and Fabrizio Pane and Giuseppe Saglio and Giovanni Martinelli and Gianantonio Rosti and Michele Baccarani",
year = "2008",
month = "5",
doi = "10.3324/haematol.12265",
language = "English",
volume = "93",
pages = "770--774",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "5",

}

TY - JOUR

T1 - Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α

T2 - 5-year outcome

AU - Palandri, Francesca

AU - Iacobucci, Ilaria

AU - Castagnetti, Fausto

AU - Testoni, Nicoletta

AU - Poerio, Angela

AU - Amabile, Marilina

AU - Breccia, Massimo

AU - Intermesoli, Tamara

AU - Iuliano, Francesco

AU - Rege-Cambrin, Giovanna

AU - Tiribelli, Mario

AU - Miglino, Maurizio

AU - Pane, Fabrizio

AU - Saglio, Giuseppe

AU - Martinelli, Giovanni

AU - Rosti, Gianantonio

AU - Baccarani, Michele

PY - 2008/5

Y1 - 2008/5

N2 - In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg daily and pegylated interferon-α in the treatment of 76 early chronic phase Philadelphia-positive chronic myeloid leukemia patients. In this report, we update the results with an observation time of five years. After two years of treatment, all but 10 patients (13%) had discontinued pegylated interferon-α. The complete cytogenetic response rate at five years was 87%, and 94% of complete cytogenetic responders maintained the complete cytogenetic response after five years. All but one complete cytogenetic response also achieved a major molecular response. These data confirm the excellent response to imatinib front-line and the stability of the complete cytogenetic response. Any possible additional benefit of the combination with interferon-a remains uncertain, due to low patient compliance.

AB - In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg daily and pegylated interferon-α in the treatment of 76 early chronic phase Philadelphia-positive chronic myeloid leukemia patients. In this report, we update the results with an observation time of five years. After two years of treatment, all but 10 patients (13%) had discontinued pegylated interferon-α. The complete cytogenetic response rate at five years was 87%, and 94% of complete cytogenetic responders maintained the complete cytogenetic response after five years. All but one complete cytogenetic response also achieved a major molecular response. These data confirm the excellent response to imatinib front-line and the stability of the complete cytogenetic response. Any possible additional benefit of the combination with interferon-a remains uncertain, due to low patient compliance.

KW - Chronic myeloid leukemia

KW - Imatinib

KW - Interferon-alpha

KW - Long-term results

UR - http://www.scopus.com/inward/record.url?scp=43449118108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43449118108&partnerID=8YFLogxK

U2 - 10.3324/haematol.12265

DO - 10.3324/haematol.12265

M3 - Article

VL - 93

SP - 770

EP - 774

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 5

ER -